Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 3
1990 3
1991 3
1992 1
1993 2
1994 2
1995 6
1996 6
1997 1
1998 2
1999 6
2000 10
2001 11
2002 14
2003 21
2004 22
2005 39
2006 60
2007 60
2008 60
2009 97
2010 112
2011 125
2012 122
2013 135
2014 115
2015 150
2016 136
2017 111
2018 116
2019 138
2020 125
2021 116
2022 113
2023 111
2024 56
2025 1

Text availability

Article attribute

Article type

Publication date

Search Results

1,923 results

Results by year

Filters applied: . Clear all
Page 1
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.
DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, McNamara J, Lowe ES, Ah-See ML, Moore KN; SOLO1 Investigators. DiSilvestro P, et al. Among authors: kim bg. J Clin Oncol. 2023 Jan 20;41(3):609-617. doi: 10.1200/JCO.22.01549. Epub 2022 Sep 9. J Clin Oncol. 2023. PMID: 36082969 Free PMC article. Clinical Trial.
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.
Banerjee S, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Oza A, González-Martín A, Aghajanian C, Bradley WH, Holmes E, Lowe ES, DiSilvestro P. Banerjee S, et al. Among authors: kim bg. Lancet Oncol. 2021 Dec;22(12):1721-1731. doi: 10.1016/S1470-2045(21)00531-3. Epub 2021 Oct 26. Lancet Oncol. 2021. PMID: 34715071 Clinical Trial.
Noncanonical PDK4 action alters mitochondrial dynamics to affect the cellular respiratory status.
Thoudam T, Chanda D, Sinam IS, Kim BG, Kim MJ, Oh CJ, Lee JY, Kim MJ, Park SY, Lee SY, Jung MK, Mun JY, Harris RA, Ishihara N, Jeon JH, Lee IK. Thoudam T, et al. Among authors: kim bg. Proc Natl Acad Sci U S A. 2022 Aug 23;119(34):e2120157119. doi: 10.1073/pnas.2120157119. Epub 2022 Aug 15. Proc Natl Acad Sci U S A. 2022. PMID: 35969774 Free PMC article.
Editorial: Systems biocatalysis for bioprocess design.
Wohlgemuth R, Littlechild J, Kim BG. Wohlgemuth R, et al. Among authors: kim bg. Front Bioeng Biotechnol. 2022 Nov 9;10:1010174. doi: 10.3389/fbioe.2022.1010174. eCollection 2022. Front Bioeng Biotechnol. 2022. PMID: 36440437 Free PMC article. No abstract available.
Enhanced Ca2+-channeling complex formation at the ER-mitochondria interface underlies the pathogenesis of alcohol-associated liver disease.
Thoudam T, Chanda D, Lee JY, Jung MK, Sinam IS, Kim BG, Park BY, Kwon WH, Kim HJ, Kim M, Lim CW, Lee H, Huh YH, Miller CA, Saxena R, Skill NJ, Huda N, Kusumanchi P, Ma J, Yang Z, Kim MJ, Mun JY, Harris RA, Jeon JH, Liangpunsakul S, Lee IK. Thoudam T, et al. Among authors: kim bg. Nat Commun. 2023 Mar 27;14(1):1703. doi: 10.1038/s41467-023-37214-4. Nat Commun. 2023. PMID: 36973273 Free PMC article.
Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial.
Youn JW, Hur SY, Woo JW, Kim YM, Lim MC, Park SY, Seo SS, No JH, Kim BG, Lee JK, Shin SJ, Kim K, Chaney MF, Choi YJ, Suh YS, Park JS, Sung YC. Youn JW, et al. Among authors: kim bg. Lancet Oncol. 2020 Dec;21(12):1653-1660. doi: 10.1016/S1470-2045(20)30486-1. Lancet Oncol. 2020. PMID: 33271094 Clinical Trial.
Structure of the Human TELO2-TTI1-TTI2 Complex.
Kim Y, Park J, Joo SY, Kim BG, Jo A, Lee H, Cho Y. Kim Y, et al. Among authors: kim bg. J Mol Biol. 2022 Jan 30;434(2):167370. doi: 10.1016/j.jmb.2021.167370. Epub 2021 Nov 24. J Mol Biol. 2022. PMID: 34838521
Polygenic risk modeling for prediction of epithelial ovarian cancer risk.
Dareng EO, Tyrer JP, Barnes DR, Jones MR, Yang X, Aben KKH, Adank MA, Agata S, Andrulis IL, Anton-Culver H, Antonenkova NN, Aravantinos G, Arun BK, Augustinsson A, Balmaña J, Bandera EV, Barkardottir RB, Barrowdale D, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bermisheva M, Bernardini MQ, Bjorge L, Black A, Bogdanova NV, Bonanni B, Borg A, Brenton JD, Budzilowska A, Butzow R, Buys SS, Cai H, Caligo MA, Campbell I, Cannioto R, Cassingham H, Chang-Claude J, Chanock SJ, Chen K, Chiew YE, Chung WK, Claes KBM, Colonna S; GEMO Study Collaborators; GC-HBOC Study Collaborators; EMBRACE Collaborators; Cook LS, Couch FJ, Daly MB, Dao F, Davies E, de la Hoya M, de Putter R, Dennis J, DePersia A, Devilee P, Diez O, Ding YC, Doherty JA, Domchek SM, Dörk T, du Bois A, Dürst M, Eccles DM, Eliassen HA, Engel C, Evans GD, Fasching PA, Flanagan JM, Fortner RT, Machackova E, Friedman E, Ganz PA, Garber J, Gensini F, Giles GG, Glendon G, Godwin AK, Goodman MT, Greene MH, Gronwald J; OPAL Study Group; AOCS Group; Hahnen E, Haiman CA, Håkansson N, Hamann U, Hansen TVO, Harris HR, Hartman M, Heitz F, Hildebrandt MAT, Høgdall E, Høgdall CK, Hopper JL, Huang RY, Huff C, Hulick PJ, Huntsman DG, Imyanitov EN… See abstract for full author list ➔ Dareng EO, et al. Among authors: kim bg. Eur J Hum Genet. 2022 Mar;30(3):349-362. doi: 10.1038/s41431-021-00987-7. Epub 2022 Jan 14. Eur J Hum Genet. 2022. PMID: 35027648 Free PMC article.
1,923 results